Last update April 15, 2024
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Израдипин is Isradipine in Cyrillic.
Is written in other languages:Израдипин belongs to these groups or families:
Main tradenames from several countries containing Израдипин in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 15 - 24 | % |
Molecular weight | 371 | daltons |
Protein Binding | 95 | % |
VD | 3.9 | l/Kg |
pKa | 16.95 | - |
Tmax | 2 - 7 | hours |
T½ | 8.4 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a dihydropyridine-type calcium channel blocker with actions similar to those of nifedipine. It is used in the treatment of hypertension. Oral administration twice daily.
At latest update no published data were found on excretion into breast milk.
Its high plasma protein binding capacity and very wide volume of distribution makes it highly unlikely a passage into breast milk.
Although it has a low oral bioavailability this may increase by 20% when administered with a meal, which would increase the oral absorption in the infant.
Evidence on other antihypertensive drugs of the same family with similar structure, pharmacokinetics and action profile (nifedipine, nimodipine, nicardipine) has shown that they are excreted into milk in non-significant amount.
Expert authors consider the use of this medication possible during breastfeeding. (Hale, Malachias 2016, Briggs 2015)
Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug should be used, especially during the neonatal period and/or in case of premature infants.